keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/28436380/tenofovir-disoproxil-fumarate-monotherapy-is-superior-to-entecavir-adefovir-combination-therapy-in-patients-with-suboptimal-response-to-lamivudine-adefovir-therapy-for-nucleoside-resistant-hbv-a-96-week-prospective-multicenter-trial
#1
Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim, Baek Gyu Jun, Young Don Kim, Dae Won Jun, Joo Hyun Sohn, Tae Yeob Kim, Byung Seok Lee
BACKGROUND: A complete virologic response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging hepatitis B virus (HBV) mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses to long-term lamivudine-adefovir dipivoxil (LAM-ADV) therapy for nucleoside analogue-resistant chronic hepatitis B...
April 24, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28427875/easl-2017-clinical-practice-guidelines-on-the-management-of-hepatitis-b-virus-infection
#2
Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L A Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase...
April 18, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28427123/-predictive-value-of-liver-pathologic-changes-in-determining-the-effectiveness-of-entecavir-treatment-for-chronic-hepatitis-b-an-analysis-of-1-366-cases
#3
M M Sun, W Zhang, G Chen, Y An, Y Q Wang, Q H Shang
Objective: To analyze the relationship between baseline liver pathologic changes and the effectiveness of entecavir(ETV) and investigate the predictive value of baseline liver pathologic changes in determining the effectiveness of ETV, to provide reliable basis for precision medicine in patients with chronic hepatitis B(CHB). Methods: A total of 1 366 cases with CHB were retrospectively recruited who underwent liver biopsy between January 2006 to June 2016 and were treated with ETV over 96 weeks.The relationship between baseline liver pathologic changes and the antiviral responses to ETV at 48, 96 weeks were compared...
April 18, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28425405/cost-effectiveness-and-clinical-impact-of-antiviral-strategies-of-hbeag-positive-and-negative-chronic-hepatitis-b
#4
Itziar Oyagüez, María Buti, Max Brosa, Magdalena Rueda, Miguel A Casado
INTRODUCTION: Chronic hepatitis B (CHB) is associated with high burden and healthcare costs. Virologic response achieved with antivirals is associated with progression avoidance. This study aimed to estimate the efficiency and clinical impact of antiviral strategies in CHB patients. MATERIAL AND METHODS: A Markov model estimated lifetime complications and direct costs in both, HBeAg-positive and HBeAg-negative cohorts. Strategy 1 (71% of treated population) and strategy 2 (100%), both based on pegylated interferon (peg-IFN) followed by oral tenofovir or entecavir, were compared to no treatment...
May 2017: Annals of Hepatology
https://www.readbyqxmd.com/read/28418595/validation-of-page-b-model-in-asian-chronic-hepatitis-b-patients-receiving-entecavir-or-tenofovir
#5
Mi Na Kim, Seong Gyu Hwang, Kyu Sung Rim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
BACKGROUND & AIMS: A new hepatocellular carcinoma (HCC) risk prediction model, PAGE-B, which includes age, gender, and platelet count as constituent variables, has recently been proposed in Caucasian chronic hepatitis B (CHB) patients. We validated PAGE-B model and compared its accuracy with that of conventional risk prediction models in Asian CHB patients. METHODS: CHB patients treated with entecavir or tenofovir were consecutively recruited. The performance of PAGE-B and three conventional risk prediction models (CU-HCC, GAG-HCC, and REACH-B) were analyzed...
April 18, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28407787/glucose-regulated-protein-78-demonstrates-antiviral-effects-but-is-more-suitable-for-hepatocellular-carcinoma-prevention-in-hepatitis-b
#6
Nai Q Zheng, Zi H Zheng, Hai X Xu, Ming X Huang, Xiao M Peng
BACKGROUND: Hepatitis B virus (HBV) is the leading cause of liver cirrhosis and hepatocellular carcinoma in Asia and Africa. Existing antivirals cannot cure HBV or eliminate risk of hepatocellular carcinoma. Glucose-regulated protein 78 (GRP78) can inhibit HBV replication, but promote virion secretion and hepatocellular cancer cell invasion. For these reasons, the overall effect of GRP78 on HBV production and whether to utilize the HBV replication-inhibitory effect of GRP78 up-regulation or the hepatocellular cancer cell invasion-inhibitory effect of its down-regulation were further investigated in order to improve the efficacy of current antiviral therapy...
April 13, 2017: Virology Journal
https://www.readbyqxmd.com/read/28404890/perioperative-entecavir-for-patients-with-hbv-related-hepatocellular-carcinoma-and-low-levels-of-viral-dna-analysis-using-propensity-score-matching
#7
Bao-Hong Yuan, Ru-Hong Li, Wei-Ping Yuan, Bang-De Xiang, Ming-Hua Zheng, Tian Yang, Jian-Hong Zhong, Le-Qun Li
The safety and efficacy of perioperative antiviral therapy for patients with hepatitis B virus related hepatocellular carcinoma and low serum levels of hepatitis B virus DNA are unknown. This retrospective study compared serum levels of hepatitis B virus DNA, liver function, morbidity, and length of hospital stay between patients who underwent hepatic resection alone and patients who received entecavir therapy before and after resection (n = 44 in each group). Propensity score matching was used to reduce confounding due to baseline differences between the groups...
February 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28392234/selection-of-the-highly-replicative-and-partially-multidrug-resistant-rts78t-polymerase-mutation-in-two-patients-with-chronic-hepatitis-b-virus-infection-during-tenofovir-entecavir-combination-therapy
#8
Elham Shirvani-Dastgerdi, Benjamin Y Winer, Antoni Celia-Terrassa, Yibin Kang, David Tabernero, Eray Yagmur, Francisco Rodríguez-Frías, Josep Gregori, Tom Luedde, Christian Trautwein, Alexander Ploss, Frank Tacke
Patients chronically infected with the hepatitis B virus (HBV) that are on long-term treatment with nucleoside or nucleotide analogues are at risk of selecting HBV strains with complex mutational patterns. We herein report two cases of HBV-infected patients with insufficient viral suppression despite dual antiviral therapy with entecavir (ETV) and tenofovir (TDF), of which one patient died from aggressive hepatocellular carcinoma (HCC). Ultra-deep pyrosequencing analyses revealed the selection of the rtS78T polymerase mutation in both cases that creates a premature stop codon at sC69 and thereby deletes almost the entire small HBV surface protein...
April 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28376852/antiviral-efficacy-of-entecavir-for-hepatitis-b-virus-rta181v-t-mutants
#9
Ping Li, Jiabao Geng, Wei Li, Xiaobing Xu, Xin Zhang, Wenkai Zheng, Yuecheng Yu, Zhiguo Yang, Maorong Wang
BACKGROUND: The amino acid substitution at position 181 of the Hepatitis B virus (HBV) polymerase is a multi-drug resistance affecting both the L-nucleoside and acyclic phosphonate nucleotide groups. Data is limited on the efficacy of entecavir (ETV) rescuing chronic hepatitis B (CHB) patients with rtA181T/V mutation. METHODS: Thirty-one patients with rtA181T/V mutation and 25 patients with rtA181T/V and rtN236T mutation were enrolled. Virological, serological and biochemical outcomes of ETV rescue therapy over 12 months in CHB patients with rtA181T/V mutation strains were investigated...
April 4, 2017: Virology Journal
https://www.readbyqxmd.com/read/28374759/human-induced-pluripotent-stem-cell-derived-hepatocyte-like-cells-as-an-in-vitro-model-of-human-hepatitis-b-virus-infection
#10
Fuminori Sakurai, Seiji Mitani, Tatsuro Yamamoto, Kazuo Takayama, Masashi Tachibana, Koichi Watashi, Takaji Wakita, Sayuki Iijima, Yasuhito Tanaka, Hiroyuki Mizuguchi
In order to understand the life cycle of hepatitis B virus (HBV) and to develop efficient anti-HBV drugs, a useful in vitro cell culture system which allows HBV infection and recapitulates virus-host interactions is essential; however, pre-existing in vitro HBV infection models are often problematic. Here, we examined the potential of human induced-pluripotent stem (iPS) cell-derived hepatocyte-like cells (iPS-HLCs) as an in vitro HBV infection model. Expression levels of several genes involved in HBV infection, including the sodium taurocholate cotransporting polypeptide (NTCP) gene, were gradually elevated as the differentiation status of human iPS cells proceeded to iPS-HLCs...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28374496/a-randomized-prospective-study-showing-the-non-inferiority-of-tenofovir-to-entecavir-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#11
Kazuhiko Koike, Kazuaki Suyama, Hiroshi Ito, Hiroshi Itoh, Wataru Sugiura
AIM: The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) and entecavir hydrate (ETV) in nucleos(t)ide analogue (NA)-naïve Japanese chronic hepatitis B (CHB) patients. METHODS: This multi-center, randomized, double-blinded study assessing the efficacy and safety of TDF 300 mg and ETV 0.5 mg in NA-naïve CHB subjects was conducted from November 2011 to November 2014, and funded by GSK. The subjects were assigned to the TDF arm or ETV arm in a 2:1 ratio...
April 3, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28373196/development-of-a-novel-site-specific-pegylated-interferon-beta-for-antiviral-therapy-for-chronic-hepatitis-b
#12
Masataka Tsuge, Takuro Uchida, Nobuhiko Hiraga, Hiromi Kan, Grace Naswa Makokha, Hiromi Abe-Chayama, Daiki Miki, Michio Imamura, Hidenori Ochi, C Nelson Hayes, Rieko Shimozono, Tomokatsu Iwamura, Hideki Narumi, Tomohiko Suzuki, Mie Kainoh, Tadatsugu Taniguchi, Kazuaki Chayama
Although nucleot(s)ide analogues and pegylated-interferon-α2a (PEG-IFNα2a) can suppress hepatitis B virus (HBV) replication, it is difficult to achieve complete HBV elimination from hepatocytes. A novel site-specific pegylated recombinant human IFNβ (TRK-560) was recently developed. In the present study, we evaluated the antiviral effects of TRK-560 on HBV replication in vitro and in vivoIn vitro and in vivo HBV replication models were treated with antivirals including TRK-560, and changes in HBV markers were evaluated...
April 3, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28370419/monotherapy-with-tenofovir-disoproxil-fumarate-for-multiple-drug-resistant-chronic-hepatitis-b-3-year-trial
#13
Young-Suk Lim, Yung Sang Lee, Geum-Youn Gwak, Kwan Soo Byun, Yoon Jun Kim, Jonggi Choi, Jihyun An, Han Chu Lee, Byung Chul Yoo, So Young Kwon
Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir, respectively. Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear...
March 30, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28370215/long-term-outcomes-of-entecavir-monotherapy-for-chronic-hepatitis-b-after-liver-transplantation-results-up-to-8-years
#14
James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan-To Cheung, Jeff Dai, Sui-Ling Sin, Ka-Wing Ma, Kelvin Ng, Kevin Ng, Wai-Kay Seto, Ching-Lung Lai, Man- Fung Yuen, Chung-Mau Lo
Long-term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B (CHB) after liver transplantation. We determined the long-term outcome of 265 consecutive CHB liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin (HBIG). Viral serology, viral load, and liver biochemistry were performed at regular intervals during follow-up. The median duration of follow up was 59 months. The cumulative rates of hepatitis B surface antigen (HBsAg) seroclearance were 90% and 95% at 1 and 5 years respectively...
March 31, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28366165/hepatitis-b-virus-induced-cytoplasmic-antineutrophil-cytoplasmic-antibody-mediated-vasculitis-causing-subarachnoid-hemorrhage-acute-transverse-myelitis-and-nephropathy-a-case-report
#15
Utsav Joshi, Roshan Subedi, Bikram Prasad Gajurel
BACKGROUND: Transverse myelitis, subarachnoid hemorrhage, and nephropathy are established but rare complications of hepatitis B virus infection that can potentially be triggered by an antibody-mediated vasculitis as a result of a viral infection. The following is a case report detailing a patient presenting with all three of the above presentations who is cytoplasmic antineutrophil cytoplasmic antibody-positive and a chronic carrier of hepatitis B. CASE PRESENTATION: A 33-year-old Nepalese man presented to our hospital with headache, swelling of his body, paraplegia, and back pain that developed over a period of 10 days...
April 3, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28350873/on-treatment-hbv-dna-dynamics-predict-virological-breakthrough-in-entecavir-treated-hbeag-positive-chronic-hepatitis-b
#16
Yi-Jie Huang, Chi-Sen Chang, Yen-Chun Peng, Hong-Zen Yeh, Sheng-Shun Yang
BACKGROUND & AIMS: Virological breakthrough (VBT) could be a manifestation of chronic hepatitis B (CHB) in patients treated with long-term nucleot(s)ide analogues. We aimed to determine the association of on-treatment serum hepatitis B virus (HBV) DNA with VBT in HBeAg-positive CHB patients receiving entecavir (ETV) treatment. METHODS: A retrospective cohort study, including 162 consecutive patients (95 men and 67 women; mean age, 43.1±13.4 years) with HBeAg-positive CHB treated with ETV for at least 48 weeks between August 2008 and May 2015, was conducted...
2017: PloS One
https://www.readbyqxmd.com/read/28345181/hbsag-kinetics-during-treatment-with-nucleos-t-ides-analogues-in-patients-with-hbeag-negative-chronic-hepatitis-b
#17
Athanasia Striki, Spilios Manolakopoulos, Melanie Deutsch, Anastasia Kourikou, George Kontos, Hariklia Kranidioti, Emilia Hadziyannis, George Papatheodoridis
BACKGROUND/AIMS: Serum HBsAg levels might be used as predictor of virological breakthrough or of sustained off-treatment virological response in HBeAg-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. METHODS: We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11, telbivudine: 16) and 86 HBeAg-negative CHB patients under entecavir or tenofovir for a mean of 30 months as the comparison group...
March 26, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28345157/entecavir-maleate-versus-entecavir-in-chinese-chronic-hepatitis-b-predominantly-genotype-b-or-c-results-at-week-144
#18
Jing-Hang Xu, Sa Wang, Zhong-Nan Xu, Yan-Yan Yu, Chong-Wen Si, Zheng Zeng, Jun Li, Mao Qing, Da-Zhi Zhang, Hong Tang, Ji-Fang Sheng, Xin-Yue Chen, Qin Ning, Guang-Feng Shi, Qing Xie, Xi-Quan Zhang, Jun Dai
Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5mg/day entecavir (group A) or 0.5mg/day entecavir maleate (group B), then all patients received treatment with 0.5mg/day entecavir maleate from week 49. Two hundred and seventy-five patients with CHB (HBeAg-positive: 218) were analyzed, predominantly (98...
March 26, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28338458/hepatitis-b-in-solid-organ-transplant-procedures-other-than-liver
#19
Dina Halegoua-De Marzio, Jonathan M Fenkel, Cataldo Doria
Transplant is often the best treatment available for patients with end-stage organ failure. Hepatitis B virus infection in transplant procedures other than liver is a major concern because it can be a significant cause of morbidity and mortality after transplant. Due to the increased risk of hepatic complications, such as fibrosing cholestatic hepatitis or histologic deterioration after transplant, systematic use of nucleoside or nucleotide analogues shortly before or at the time of transplant is recommended (tenofovir or entecavir are preferable to lamivudine) in all patients, whatever the baseline histologic evaluation...
April 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/28332360/entecavir-to-telbivudine-switch-therapy-in-entecavir-treated-patients-with-undetectable-hepatitis-b-viral-dna
#20
Dong Hyun Kim, Jong Won Choi, Jeong Hun Seo, Yong Suk Cho, Sun Young Won, Byung Kyu Park, Han Ho Jeon, Sang Yun Shin, Chun Kyon Lee
PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase level after the initial 6 months of ETV treatment. MATERIALS AND METHODS: Sixty subjects were randomized to continue with ETV or switch to LdT. Significant difference in baseline characteristics was not found between the two groups. Persistent HBV DNA level of 20-60 IU/mL in three consecutive samples collected three months apart or singly measured HBV DNA level of >60 IU/mL was defined as virological rebound...
May 2017: Yonsei Medical Journal
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"